Please ensure Javascript is enabled for purposes of website accessibility

Abbott Receives FDA Authorization for a $5 App-Enabled 15-Minute COVID-19 Test

By Brian Orelli, PhD – Aug 26, 2020 at 8:35PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The cheap, rapid test could help get people back to work.

The biggest issues with COVID-19 testing have been speed and cost. Abbott Laboratories' (ABT) newest offering seems to have those covered, and the healthcare company is even providing a phone app that will display negative results for customers who need to prove that they're not infected with the novel coronavirus that causes COVID-19.

Abbott's BinaxNOW COVID-19 Ag Card test, which is about the size of a credit card, can generate a result in 15 minutes and costs $5 per sample. The test, which was issued an emergency use authorization by the Food and Drug Administration, detects viral proteins to determine if the patient has been infected with the novel coronavirus. Results of the test will show up on Abbott's free Navica app, which will be available for both iPhone and Android devices.

Patient in a car getting a nasal swab

Image source: Getty Images.

Unlike molecular tests, which detect viral RNA, Abbott's test doesn't require additional hardware. The test can't be self administered, but a wide range of practitioners, including doctors, nurses, school nurses, medical assistants and technicians, pharmacists and employer occupational health specialists, are able to run the test.

The BinaxNOW COVID-19 Ag Card test isn't perfect. It has a sensitivity of 97.1%, meaning 2.9% of positive cases will be missed, and a specificity of 98.5%, meaning 1.5% of people will test positive even though they don't have COVID-19. Despite the small expected inaccuracies, the results are pretty good for a cheap test that only takes 15 minutes to run.

Abbott plans to ship tens of millions of tests in September and will ramp up to 50 million tests a month at the beginning of October.

Brian Orelli, PhD and The Motley Fool have no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
ABT

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
339%
 
S&P 500 Returns
110%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 10/06/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.